Adopting novel technologies to improve monoclonal antibody processes

Over last 20+ year there has been significant grown in monoclonal antibody drug pipeline as well as diversity of monoclonal antibody molecules.

For example, the diversity not only includes different isoforms but also bi-specific, tri-specific, multi-specific to fragments. This diversity presents significant challenges to develop and commercialize the novel drug while meeting commercial demand from the existing molecules. This presentation will illustrate approaches to overcome these challenges by implementing novel technologies such as buffer/media supplement delivery, fluid movement using single use systems to improve current plant efficiency, streamline downstream processes and new viral inactivation approach for new class of multi-specifics antibodies.

This presentation was given during BioProduction, part of CPhI, November 3, 2022.

Presented by:

Dr. Nandu Deorkar Senior Vice President, Research & Development – Biopharma Production, Avantor Nandu Deorkar is Senior Vice President, Biopharma Production Research & Development for Avantor. He is responsible for innovation strategy and planning, and execution of new products and technology development. During his more than 25-year career in research & development, Dr. Deorkar has been leading teams working on various aspects of upstream and downstream bioprocessing, single use systems, chemical/polymer R&D, drug development, formulation, drug delivery technologies, process development, and technology transfer. He has published more than 30 articles and holds more than 20 patents. Dr. Deorkar received Ph.D. from Indian Institute of Technology, Mumbai, India and MBA in Marketing from Fairleigh Dickinson University, Madison, NJ, USA.